Thromboembolic events in testicular cancer patients during cisplatin-containing chemotherapy, both arterial and venous, pose an important problem for various reasons. First, thromboembolic events can result in considerable morbidity and mortality. Second, thromboembolic events can interfere with the continuation of a potentially curative chemotherapy and thus reduce the chance of cure. Finally, thromboembolic events during chemotherapy may predict vascular events in the long term, either as a sign of irreversible damage or as a sign that the patients involved are vulnerable to vascular damage in general. Therefore, more information is needed about the pathogenetic and predictive factors for and preventive measures against thromboembolic events during and after chemotherapy for testicular cancer.